Publications (original articles or review articles) published in 2019 from OUS - Section for Breast Oncology
12 publications found
Immune stimulatory effect of anti-EpCAM immunotoxin - improved overall survival of metastatic colorectal cancer patients
Acta Oncol, 59 (4), 404-409
DOI 10.1080/0284186X.2019.1704864, PubMed 31876430
Employment Status and Work Ability in Long-Term Young Adult Cancer Survivors
J Adolesc Young Adult Oncol, 8 (3), 304-311
DOI 10.1089/jayao.2018.0109, PubMed 30900929
Assessing Treatment Response and Prognosis by Serum and Tissue Metabolomics in Breast Cancer Patients
J Proteome Res, 18 (10), 3649-3660
DOI 10.1021/acs.jproteome.9b00316, PubMed 31483662
Using clinical cancer registry data for estimation of quality indicators: Results from the Norwegian breast cancer registry
Int J Med Inform, 125, 102-109
DOI 10.1016/j.ijmedinf.2019.03.004, PubMed 30914174
Breast cancer quantitative proteome and proteogenomic landscape
Nat Commun, 10 (1), 1600
DOI 10.1038/s41467-019-09018-y, PubMed 30962452
Transient redirection of T cells for adoptive cell therapy with telomerase-specific T helper cell receptors isolated from long term survivors after cancer vaccination
Oncoimmunology, 8 (4), e1565236
DOI 10.1080/2162402X.2019.1565236, PubMed 30906659
Toward Personalized Computer Simulation of Breast Cancer Treatment: A Multiscale Pharmacokinetic and Pharmacodynamic Model Informed by Multitype Patient Data
Cancer Res, 79 (16), 4293-4304
DOI 10.1158/0008-5472.CAN-18-1804, PubMed 31118201
miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer
Mol Oncol, 13 (10), 2278-2296
DOI 10.1002/1878-0261.12561, PubMed 31402562
Decreasing waiting time for treatment before and during implementation of cancer patient pathways in Norway
Cancer Epidemiol, 61, 59-69
DOI 10.1016/j.canep.2019.05.004, PubMed 31153048
Serum levels of inflammation-related markers and metabolites predict response to neoadjuvant chemotherapy with and without bevacizumab in breast cancers
Int J Cancer, 146 (1), 223-235
DOI 10.1002/ijc.32638, PubMed 31444972
Inflammatory serum markers and risk and severity of prostate cancer: The PROCA-life study
Int J Cancer, 147 (1), 84-92
DOI 10.1002/ijc.32718, PubMed 31583707
An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment
Nat Commun, 10 (1), 5499
DOI 10.1038/s41467-019-13329-5, PubMed 31796750